The clinical pharmacological review of cefepime/taniborbactam:a new type β-lactamase inhibitor complex formulation
XIN Ming-ming
MA Xu-zhu
DONG Jing
LIN Ming-gui
Abstract：Bacterial resistance is increasing exponentially worldwide,especially in carbapenem resistant Gram negative bacteria,but effective therapeutic drugs are very limited.Taniborbactam is a novel cyclic borate ester β-lactamase inhibitor.It has a strong inhibitory effect on serine and metallo-β-lactamases(Ambler classes A,B,C and D).Currently,taniborbactam is combined with cefepime for new drug development,with the potential to address this medication demand.This article provides a review on the mechanism,pharmacodynamics,and pharmacokinetic clinical studies in cefepime/taniborbactam.
Keywords：β-lactamasescefepimetaniborbactampharmacodynamicspharmacokinetics
Publication Date：2024-11-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 2272-2277 )